Journal article
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial
Abstract
BACKGROUND: Oesophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and Barrett's oesophagus is the biggest risk factor. We aimed to evaluate the efficacy of high-dose esomeprazole proton-pump inhibitor (PPI) and aspirin for improving outcomes in patients with Barrett's oesophagus.
METHODS: The Aspirin and Esomeprazole Chemoprevention in Barrett's metaplasia Trial had a 2 × 2 factorial design and was done at 84 …
Authors
Jankowski JAZ; de Caestecker J; Love SB; Reilly G; Watson P; Sanders S; Ang Y; Morris D; Bhandari P; Brooks C
Journal
The Lancet, Vol. 392, No. 10145, pp. 400–408
Publisher
Elsevier
Publication Date
August 2018
DOI
10.1016/s0140-6736(18)31388-6
ISSN
0140-6736